


Q1 What field do you work in?

Respondents: 72 Skipped: 0




ANSWER OPTIONS	ANSWERS	
Adult Hematology Clinic	73.61%	53
Pediatric Hematology/Oncology Clinic	26.39%	19
Laboratory Research	0.00%	0
TOTAL		72

S2 How many years have you been working in the field of hematology?

Answered: 72

Skipped: 0



ANSWER OPTIONS	ANSWERS	
1-5 years	20.83%	15
5-10 years	13.89%	10
>10 years	65.28%	47
TOTAL		72


S3 In which city is the organization you work for located?

Responded: 70 Skipped: 2

Q4 The organization you work for;

Answered: 71

Skipped: 1



ANSWER OPTIONS	ANSWERS	
Private Hospital	14.08%	10
Public Hospital	28.17%	20
State University	49.30%	35
Private University	8.45%	6
TOTAL		71

S5 How many patients with pre-B-ALL, B-NHL, and myeloma were treated at your clinic in the past year? (a) 5 b) 5–10 c) >10)

Answered: 71

Skipped: 1

ANSWER OPTIONS	ANSWERS	
ALL	98.59%	70
Lymphoma	94.37%	67
Multiple myeloma	84.51%	60

S6 What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

Responded: 68 Skipped: 4

Q7 Based on current guidelines, how many of your patients should have received CAR-T therapy in the past year?

Answered: 70 Skipped: 2

Q8 Based on current guidelines, how would you categorize your patients who you believe should receive CAR-T therapy by their diagnoses?

Answered: 70

Skipped: 2

ANSWER OPTIONS	ANSWERS	
ALL count	87.14%	61
Lymphoma count	81.43%	57
Number of multiple myeloma cases	75.71%	53

S9 How many of these patients have access to CAR-T therapy?

Responded: 67 Skipped: 5

Q10 How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

Answered: 69 Skipped: 3

Q11 Which CAR-T product was used?

Answered: 21

Skipped: 51

ANSWER OPTIONS	ANSWERS	
Commercial Product (please specify product name)	85.71%	18
Academic Production (specify center)	80.95%	17

S12 Where did your patient receive CAR-T therapy?

Responded: 18 Skipped: 54


ANSWER OPTIONS	ANSWERS	
Private treatment abroad (please specify the center)	83.33%	15
Turkey (specify location)	72.22%	13
Work abroad (specify location)	55.56%	10
Work in Turkey (specify location)	55.56%	10

S13 How long after the indication arose did your patient receive CAR-T therapy?

Responded: 19 Skipped: 53

Q14 Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?


Answered: 62 Skipped: 10



ANSWER OPTIONS	ANSWERS	
Yes	96.77%	60
No	3.23%	2
TOTAL		62

Q15 What is the biggest barrier to accessing CAR-T therapy in Turkey?

Responded: 70 Skipped: 2




ANSWER OPTIONS	ANSWERS	
Cost	64.29%	45
Insufficient technological infrastructure	21.43%	15
Lack of qualified personnel	7.14%	5
Other	7.14%	5
TOTAL		70

S16 What is your reason for not referring a patient with a CAR-T indication for treatment?

Answered: 69


Skipped: 3



ANSWER OPTIONS	ANSWERS	
Problem accessing treatment	88.41%	61
Time until treatment is received	2.90%	2
Serious side effects	1.45%	1
You do not believe it will make a significant difference in effectiveness	1.45%	1
Other	5.80%	4
TOTAL		69

S17 If you had access to CAR-T therapy for your relapsed patients as part of a national and/or international clinical trial, would you use it?

Responded: 70 Skipped: 2



ANSWER OPTIONS	ANSWERS	
Yes	98.57%	69
No	1.43%	1
TOTAL		70